Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FavId + Rituximab + GM-CSF in Indolent B-Cell Lymphoma
NCT00258336Phase 2Unknown
- Sponsor
- Favrille, Inc.
- Start
- Aug 2004
- Primary completion
- Nov 2009
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of FavId in B-cell non-Hodgkin lymphoma (B-NHL), sponsored by Favrille, Inc.. Status: unknown.
02
Drugs
FavId
03
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)
Beyond the preview
Go deeper on NCT00258336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00258336.